Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- ER Positive Breast Cancer
- HER2 Negative Breast Cancer
- Metastatic Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04738292
- Collaborators
- Context Therapeutics
- Investigators
- Principal Investigator: Kari B Wisinski, MD University of Wisconsin, Madison Study Chair: Sailaja Kamaraju, MD, MS Medical College of Wisconsin
Get Well Soon